In the battle between weight-loss drug companies, Eli Lilly has emerged as the clear winner for investors. The maker of Zepbound and diabetes treatment Mounjaro hit a $1 trillion market cap on Friday, making it the first health-care company to break through the mark. Novo Nordisk , on the other hand, saw shares tumble 6% on Monday after its Alzheimer's trial failed to meet its main goal. The trial studied whether semaglutide, the active ingredient in its diabetes and weight loss drugs Ozempic and Wegovy, helped slow the progress of the disease. For many on Wall Street, the sell-off wasn't surprising and didn't necessarily provide a buying opportunity. Evan Seigerman, BMO Capital Markets analyst, said he prefers Eli Lilly over Novo Nordisk, even though the latter's sell-off may be overdone.

See Full Page